Soley Bayraktar

Summary

Publications

  1. pmc Association between Tumor Characteristics and Bone Mineral Density in Postmenopausal Breast Cancer Patients
    Soley Bayraktar
    Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Breast J 19:431-4. 2013
  2. pmc Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations
    S Bayraktar
    Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Clin Exp Metastasis 30:631-42. 2013
  3. doi request reprint Molecularly targeted therapies for metastatic triple-negative breast cancer
    Soley Bayraktar
    Department of Medical Oncology, Mercy Cancer Center, Ardmore, OK, USA
    Breast Cancer Res Treat 138:21-35. 2013
  4. pmc Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer
    Soley Bayraktar
    Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:2385-93. 2012
  5. pmc USP-11 as a predictive and prognostic factor following neoadjuvant therapy in women with breast cancer
    Soley Bayraktar
    Departmentsof Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer J 19:10-7. 2013
  6. doi request reprint Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ
    Soley Bayraktar
    Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 118:1515-22. 2012
  7. pmc The relationship between eight GWAS-identified single-nucleotide polymorphisms and primary breast cancer outcomes
    Soley Bayraktar
    Department of Medical Oncology, Mercy Cancer Center, Ardmore, Oklahoma, USA
    Oncologist 18:493-500. 2013
  8. pmc Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer
    Soley Bayraktar
    Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 118:1202-11. 2012
  9. doi request reprint Dose-dense chemotherapy for breast cancer
    Soley Bayraktar
    Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Breast J 18:261-6. 2012
  10. doi request reprint Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience
    Banu Arun
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1354, Houston, TX 77030 4009, USA
    J Clin Oncol 29:3739-46. 2011

Detail Information

Publications14

  1. pmc Association between Tumor Characteristics and Bone Mineral Density in Postmenopausal Breast Cancer Patients
    Soley Bayraktar
    Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Breast J 19:431-4. 2013
    ..05). Higher baseline BMD in postmenopausal patients with breast cancer is associated with favorable prognostic features...
  2. pmc Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations
    S Bayraktar
    Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Clin Exp Metastasis 30:631-42. 2013
    ..Our data indicate that BRCA1 carriers diagnosed with MBC have worse outcomes compared to BRCA2 carriers and non-carriers. However, the differences in outcome did not reach statistical significance likely due to small sample sizes...
  3. doi request reprint Molecularly targeted therapies for metastatic triple-negative breast cancer
    Soley Bayraktar
    Department of Medical Oncology, Mercy Cancer Center, Ardmore, OK, USA
    Breast Cancer Res Treat 138:21-35. 2013
    ..Several of these agents have shown considerable promise...
  4. pmc Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer
    Soley Bayraktar
    Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:2385-93. 2012
    ....
  5. pmc USP-11 as a predictive and prognostic factor following neoadjuvant therapy in women with breast cancer
    Soley Bayraktar
    Departmentsof Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer J 19:10-7. 2013
    ..We sought to examine the predictive and prognostic relevance of USP-11 in patients treated with neoadjuvant systemic therapy (NST) for breast cancer...
  6. doi request reprint Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ
    Soley Bayraktar
    Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 118:1515-22. 2012
    ..The authors of this report identified predictive factors for mutations in the breast cancer-susceptibility genes BRCA1 and BRCA2 in women who were diagnosed with DCIS...
  7. pmc The relationship between eight GWAS-identified single-nucleotide polymorphisms and primary breast cancer outcomes
    Soley Bayraktar
    Department of Medical Oncology, Mercy Cancer Center, Ardmore, Oklahoma, USA
    Oncologist 18:493-500. 2013
    ..We investigated whether eight risk SNPs identified in GWAS were associated with breast cancer disease-free survival (DFS) and overall survival (OS) rates...
  8. pmc Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer
    Soley Bayraktar
    Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 118:1202-11. 2012
    ..In the current study, the authors explored the association between metformin use and survival outcomes in patients with triple receptor-negative breast cancer (TNBC) who were receiving adjuvant chemotherapy...
  9. doi request reprint Dose-dense chemotherapy for breast cancer
    Soley Bayraktar
    Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Breast J 18:261-6. 2012
    ..Further studies are needed to define the optimal regimen and the patient population that will receive the greatest benefit from dose-dense strategy...
  10. doi request reprint Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience
    Banu Arun
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1354, Houston, TX 77030 4009, USA
    J Clin Oncol 29:3739-46. 2011
    ....
  11. doi request reprint A phase 1 trial of E7974 administered on day 1 of a 21-day cycle in patients with advanced solid tumors
    Caio M Rocha-Lima
    Department of Medical Oncology, University of Miami and Sylvester Comprehensive Cancer Center, Miami, Florida, USA
    Cancer 118:4262-70. 2012
    ..E7974, a synthetic analog of hemiasterlin, interacts with the tubulin molecule and overcomes resistance to other antitubulin drugs (taxanes and vinca alkaloids)...
  12. doi request reprint Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations
    Soley Bayraktar
    Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Breast Cancer Res Treat 130:145-53. 2011
    ..Further studies need to evaluate whether different therapies will change the outcome in these subgroups of TNBC...
  13. pmc Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinoma
    Soley Bayraktar
    Soley Bayraktar, Departments of Medical Oncology, Mercy Cancer Center, Ardmore, OK 73401, United States
    World J Clin Oncol 4:29-42. 2013
    ..In this review, we present a summary of many of the currently investigated biologic targets in NSCLC, discuss their current clinical trial status, and also discuss the potential for development of other targeted agents...
  14. doi request reprint Emerging cell-cycle inhibitors for pancreatic cancer therapy
    Soley Bayraktar
    Mercy Cancer Center, Department of Medical Oncology, 1220 Hall street, Ardmore, OK, USA
    Expert Opin Emerg Drugs 17:571-82. 2012
    ....